ReviewThe Journal of allergy and clinical immunology2026
The rhinovirus puzzle: Linking virus and host factors to childhood asthma.
Review in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Respiratory Pathogens and Clinical Characteristics of Asthma Exacerbations in Hospitalized Children at a Tertiary Hospital in Türkiye.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rhinoviruses (RVs) are the most common respiratory pathogens and a significant cause of asthma exacerbations and wheezing illnesses in children. In addition, RV wheezing illnesses during the preschool years strongly predict asthma development. This review includes updates on RV epidemiology and virus diversity, highlighting species-specific differences and antigenic variability that present significant challenges for vaccine design. Host responses to RV involve canonical antiviral responses originating in airway epithelial cells, followed by activation of adaptive immunity. In patients with asthma and allergic disease, type 2 inflammation, genetic susceptibility, and epithelial remodeling impair these antiviral defenses. These factors, combined with airway dysbiosis, can exacerbate airway injury and lead to more severe illnesses. RV infection disrupts epithelial barrier integrity, promotes pathobiont growth, and induces factors that can drive structural changes associated with airway obstruction and chronic asthma. Therapeutic strategies, including direct antivirals and interferons, show promise but remain limited by adverse effects and modest efficacy, while extreme virus diversity remains an obstacle to vaccine development. Advances in understanding how host factors, such as type 2 inflammation, increase susceptibility to RV infection and illness identify alternative approaches to reducing RV morbidity in high-risk children with allergic diseases and asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.